細(xì)胞周期素D1(CCND1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Cyclin D1 (CCND1) ,etc. by FLIA (Flow Luminescence Immunoassay)
CCN-D1; BCL1; PRAD1; U21B31; G1/S-Specific Cyclin-D1; Parathyroid Adenomatosis 1; B-Cell CLL/Lymphoma 1; G1/S-Specific Cyclin D1; PRAD1 oncogene
(注:單次混測(cè)多因子不超過8個(gè)指標(biāo) )
- 編號(hào)LMA585Mu
- 物種Mus musculus (Mouse,小鼠) 相同的名稱,不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長3.5h
- 檢測(cè)范圍0.01-10ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.003 ng/mL.
- 樣本類型tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 8指標(biāo)數(shù) 7指標(biāo)數(shù) 6指標(biāo)數(shù) 5指標(biāo)數(shù) 4指標(biāo)數(shù) 3指標(biāo)數(shù) 2指標(biāo)數(shù)1指標(biāo)數(shù)
- 價(jià)格 ¥ 2427 ¥ 2521 ¥ 2661 ¥ 2847 ¥ 3034 ¥ 3314 ¥ 3734 計(jì)算器 ¥ 4668 添加到價(jià)格計(jì)算器
- 欲了解實(shí)際交易價(jià)格和更多情況,請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
特異性
本試劑盒用于檢測(cè)細(xì)胞周期素D1(CCND1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法),經(jīng)檢測(cè)與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制,不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè),因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的細(xì)胞周期素D1(CCND1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)(加標(biāo)樣品),重復(fù)測(cè)定并計(jì)算其均值,回收率為測(cè)定值與理論值的比率。
樣本 | 回收率范圍(%) | 平均回收率(%) |
serum(n=5) | 81-104 | 86 |
EDTA plasma(n=5) | 92-105 | 101 |
heparin plasma(n=5) | 87-94 | 91 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差:取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次,分別計(jì)算不同濃度樣本的平均值及SD值。
批間差:選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定,每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次,分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差: CV<10%
批間差: CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的細(xì)胞周期素D1(CCND1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法),并倍比稀釋成1:2,1:4,1:8,1:16的待測(cè)樣本,線性范圍即為稀釋后樣本中細(xì)胞周期素D1(CCND1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)含量的測(cè)定值與理論值的比率。
樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 90-104% | 90-103% | 98-105% | 83-104% |
EDTA plasma(n=5) | 98-105% | 83-95% | 84-93% | 78-97% |
heparin plasma(n=5) | 96-105% | 93-102% | 86-105% | 80-97% |
穩(wěn)定性
經(jīng)測(cè)定,試劑盒在有效期內(nèi)按推薦溫度保存,其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響,實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致,尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備;
2. 加樣(標(biāo)準(zhǔn)品、樣本、磁珠)標(biāo)準(zhǔn)品或樣本100μL及磁珠10μL,
37°C酶標(biāo)板振蕩器孵育90分鐘;
3. 磁吸甩干,加檢測(cè)溶液A100μL,37°C酶標(biāo)板振蕩器孵育60分鐘;
4. 磁吸洗板3次;
5. 加檢測(cè)溶液B100μL,37°C振動(dòng)孵育30分鐘;
6. 磁吸洗板3次;
7. 加鞘液100μL,旋渦震蕩2分鐘后讀數(shù)。
實(shí)驗(yàn)原理
將細(xì)胞周期素D1(CCND1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體包被于磁珠,制成固相載體,向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠,其中的細(xì)胞周期素D1(CCND1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體結(jié)合,然后加入生物素化的細(xì)胞周期素D1(CCND1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體,將未結(jié)合的生物素化抗體洗凈后,加入PE標(biāo)記的親和素,再次徹底洗滌后即可上機(jī)讀數(shù)。MFI值和樣品中的細(xì)胞周期素D1(CCND1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)呈正相關(guān)。
贈(zèng)品
相關(guān)產(chǎn)品
編號(hào) | 適用物種:Mus musculus (Mouse,小鼠) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPA585Mu01 | 細(xì)胞周期素D1(CCND1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPA585Mu02 | 細(xì)胞周期素D1(CCND1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA585Mu02 | 細(xì)胞周期素D1(CCND1)多克隆抗體 | WB; IHC; ICC; IP. |
PAA585Mu01 | 細(xì)胞周期素D1(CCND1)多克隆抗體 | WB; IHC; ICC; IP. |
LAA585Mu71 | 細(xì)胞周期素D1(CCND1)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
LAA585Mu81 | 細(xì)胞周期素D1(CCND1)多克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
SEA585Mu | 細(xì)胞周期素D1(CCND1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMA585Mu | 細(xì)胞周期素D1(CCND1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
KSA585Mu01 | 細(xì)胞周期素D1(CCND1)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
Biochemical Pharmacology | Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells [ScienceDirect: S0006295211002097] |
Leukemia & Lymphoma | The nanoparticulate Quillaja saponin KGI exerts anti-proliferative effects by down-regulation of cell cycle molecules in U937 and HL-62 human leukemia cells [Pubmed: 24138332] |
The Journal of Clinical Endocrinology and Metabolism | Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1. [Pubmed: 23969186] |
Nutrition and Cancer | Common Food Additive Carrageenan Stimulates Wnt/ β-Catenin Signaling in Colonic Epithelium by Inhibition of Nucleoredoxin Reduction [Pubmed:24328990] |
The International Journal of Biochemistry &?Cell?Biology | MicroRNA-149 is epigenetically silenced tumor-suppressive microRNA, involved in cell proliferation and downregulation of AKT1 and cyclin D1 in human … [pubmed:27783537] |
Scientific Reports | Is there an association between enhanced choline and β-catenin pathway in breast cancer? A pilot study by MR Spectroscopy and ELISA. [pubmed:28533512] |
Investigational new drugs | Development of a dietary formulation of the SHetA2 chemoprevention drug for mice. [pubmed:29273857] |
Biochemical Pharmacology | Metronomic vinorelbine is directly active on Non Small Cell Lung Cancer cells and sensitizes the EGFRL858R/T790M cells to reversible EGFR tyrosine kinase?… [Pubmed:29660315] |
Apoptosis | Licarin A induces cell death by activation of autophagy and apoptosis in non-small cell lung cancer cells [Pubmed:29468481] |
Oncology?Reports | Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo [Pubmed:29517106] |
Oncology Reports | Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo [Pubmed:29517103] |
Scientific Reports | Is there an association between enhanced choline and β-catenin pathway in breast cancer? A pilot study by MR Spectroscopy and ELISA [Pubmed: 28533512] |
Middle East Journal of Rehabilitation and Health | Antiapoptotic Effects of Continuous Training and Selenium Consumption on the Liver Tissue of Cadmium-Exposed Rats [Pubmed: 10.5812/mejrh.91278] |
European journal of medicinal chemistry | Synthesis of novel S-linked dihydroartemisinin derivatives and evaluation of their anticancer activity [Pubmed: 31216504] |